Cenovus Energy Inc vs Zoetis Inc — how do they compare? Cenovus Energy Inc trades at $31.39 (market cap $57.90B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Zoetis Inc for 70 Days on average.
| CVE | ZTS | |
|---|---|---|
Market Cap | $57.90B | $30.20B |
Volume | 7,863,588 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $33.92 | $147.53 |
52-Week Low | $15.85 | $69.09 |
Typical Hold Time | 46 Days | 70 Days |
Enterprise Value | $63.84B | $37.76B |
Dividend Yield | 1.97% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 2.81% today, with a bullish technical signal and strong fundamental metrics including a P/E of 12.43 and ROE of 20.96%. The company has beaten earnings estimates in three of the last four quarters and maintains solid cash flow generation despite recent net cash outflows. Recent analyst upgrades and positive media coverage highlight growing investor confidence in the energy sector.
CVE presents a compelling value opportunity with attractive valuation ratios and strong profitability metrics. Key risks include commodity price volatility and execution challenges in capital investments. Wall Street sentiment is cautiously optimistic with 40.7% buy ratings, though the majority maintain hold positions awaiting clearer earnings momentum.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Trailing returns across standard periods
Latest headlines on both assets
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →